cancer-2018-posters-abstracts

Page 53

allied

academies

Journal of Medical Oncology and Therapeutics | Volume: 3

July 23-25, 2018 | Moscow, Russia

World Cancer Congress

Circulating tumor cells: Clinical utility, challenges and future prospects

Qing He Meng

The University of Texas MD Anderson Cancer Center, USA

he detection of CTCs has been used as useful biomarkers

in prognosis and monitoring therapeutic response

of patients with metastatic cancer. However, during the

course of cancer therapy, CTCs have undergone epithelial-

mesenchymal transition (EMT) (i.e., EMT CTCs) and the

current FDA-approved technology is unable to detect such

EMT CTCs. Using new technologies such as antibody against

cell-surface vimentin (CSV) exclusively expressed on EMT

CTCs, we are able to detect EMT CTCs from breast, colon,

and prostate tumor types and monitor disease progression

and predict the prognosis. This presentation will briefly

review the current status of CTC detection, the detection

technology and clinical utility of CTC. The challenges of the

current technology and new technology in determination

of CTC will be addressed. The detection of EMT CTCs

especially CTC with molecular profiling for cancer diagnosis,

monitoring therapeutic responses, predicting prognosis, and

guiding personalized therapy will be discussed. Detection

of CTCs and molecular characterization as one of the liquid

biopsy approach may serve as an instrumental role for

noninvasive approach in personalized cancer medicine